Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 39 h ago

OnKure Therapeutics, Inc.: Venrock Healthcare Capital Partners III, L.P. discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 20 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Venrock Healthcare Capital Partners III, L.P. disclosed a stake of more than 5% in OnKure Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001231919-26-001621). The filing signals the venture firm's sizable position in the clinical-stage biotech, though the disclosure did not specify the exact share count or percentage held. A Schedule 13G is typically used by passive investors, suggesting Venrock is not seeking control of the company. Investors will watch for further detail on the position's size and any subsequent 13G amendments, as well as OnKure's clinical progress.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

OnKure Therapeutics, Inc., Venrock Healthcare Capital Partners III, L.P.